← All trials
NCT04494191
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 12, 2018
- Primary completion
- Dec 19, 2018
- Completion date
- Feb 27, 2019
- First posted
- Jul 31, 2020
- Last posted
- Jul 31, 2020
- Enrollment
- 26
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Genuine Research Center, EgyptLead sponsor
- Genuine Research Center, EgyptStudy director
- Bio Med for Pharmaceuticals Industries (BIOMED), EgyptCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.